Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

Research output: Contribution to journalArticle

Standard

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. / Gunnarsson, Niklas; Stenke, Leif; Hoglund, Martin; Sandin, Fredrik; Bjorkholm, Magnus; Dreimane, Arta; Lambe, Mats; Markevarn, Berit; Olsson-Stromberg, Ulla; Richter, Johan; Wadenvik, Hans; Wallvik, Jonas; Sjalander, Anders.

In: British Journal of Haematology, Vol. 169, No. 5, 2015, p. 683-688.

Research output: Contribution to journalArticle

Harvard

Gunnarsson, N, Stenke, L, Hoglund, M, Sandin, F, Bjorkholm, M, Dreimane, A, Lambe, M, Markevarn, B, Olsson-Stromberg, U, Richter, J, Wadenvik, H, Wallvik, J & Sjalander, A 2015, 'Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era', British Journal of Haematology, vol. 169, no. 5, pp. 683-688. https://doi.org/10.1111/bjh.13346

APA

Gunnarsson, N., Stenke, L., Hoglund, M., Sandin, F., Bjorkholm, M., Dreimane, A., ... Sjalander, A. (2015). Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. British Journal of Haematology, 169(5), 683-688. https://doi.org/10.1111/bjh.13346

CBE

Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A, Lambe M, Markevarn B, Olsson-Stromberg U, Richter J, Wadenvik H, Wallvik J, Sjalander A. 2015. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. British Journal of Haematology. 169(5):683-688. https://doi.org/10.1111/bjh.13346

MLA

Vancouver

Author

Gunnarsson, Niklas ; Stenke, Leif ; Hoglund, Martin ; Sandin, Fredrik ; Bjorkholm, Magnus ; Dreimane, Arta ; Lambe, Mats ; Markevarn, Berit ; Olsson-Stromberg, Ulla ; Richter, Johan ; Wadenvik, Hans ; Wallvik, Jonas ; Sjalander, Anders. / Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. In: British Journal of Haematology. 2015 ; Vol. 169, No. 5. pp. 683-688.

RIS

TY - JOUR

T1 - Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

AU - Gunnarsson, Niklas

AU - Stenke, Leif

AU - Hoglund, Martin

AU - Sandin, Fredrik

AU - Bjorkholm, Magnus

AU - Dreimane, Arta

AU - Lambe, Mats

AU - Markevarn, Berit

AU - Olsson-Stromberg, Ulla

AU - Richter, Johan

AU - Wadenvik, Hans

AU - Wallvik, Jonas

AU - Sjalander, Anders

PY - 2015

Y1 - 2015

N2 - Given that tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with chronic myeloid leukaemia (CML), we were interested in examining the possible risk of long-term adverse events, such as the emergence of other neoplasms. Therefore, we studied the development of second malignancies in 868 patients diagnosed with CML between 2002 and 2011 using the Swedish CML register, cross-linked to the Swedish Cancer register. With a median follow-up of 37 (range 0-99)years, 65 (75%) patients developed 75 second malignancies (non-haematological), 52 of which were of the invasive type. Compared to expected rates in the background population, the risk of second malignancies was higher in the CML cohort, with a standardized incidence ratio (SIR) of 152 (95% CI 113-199). The SIR before and after the second year following diagnosis of CML was 158 and 147, respectively. Among specific cancer types, gastrointestinal and nose and throat cancer were significantly increased. Founded on a population-based material, our results indicate that CML patients treated in the TKI era are at an increased risk of developing a second malignancy, with indications that this risk may more likely be linked to CML itself rather than to the TKI treatment.

AB - Given that tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with chronic myeloid leukaemia (CML), we were interested in examining the possible risk of long-term adverse events, such as the emergence of other neoplasms. Therefore, we studied the development of second malignancies in 868 patients diagnosed with CML between 2002 and 2011 using the Swedish CML register, cross-linked to the Swedish Cancer register. With a median follow-up of 37 (range 0-99)years, 65 (75%) patients developed 75 second malignancies (non-haematological), 52 of which were of the invasive type. Compared to expected rates in the background population, the risk of second malignancies was higher in the CML cohort, with a standardized incidence ratio (SIR) of 152 (95% CI 113-199). The SIR before and after the second year following diagnosis of CML was 158 and 147, respectively. Among specific cancer types, gastrointestinal and nose and throat cancer were significantly increased. Founded on a population-based material, our results indicate that CML patients treated in the TKI era are at an increased risk of developing a second malignancy, with indications that this risk may more likely be linked to CML itself rather than to the TKI treatment.

KW - chronic myeloid leukaemia

KW - treatment

KW - malignancy

U2 - 10.1111/bjh.13346

DO - 10.1111/bjh.13346

M3 - Article

VL - 169

SP - 683

EP - 688

JO - British Journal of Haematology

T2 - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -